Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label dose-escalation study of SKG0201 in infants with type 1 spinal muscular atrophy
CTR20260736Phase 2Active
- Sponsor
- Lanyue Bio
- Start
- Apr 2026
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of SKG0201 in spinal muscular atrophy type 1, sponsored by Lanyue Bio. Started Apr 2026; status: active.
02
Drugs
SKG0201
03
Conditions
spinal muscular atrophy type 1
Beyond the preview
Go deeper on CTR20260736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260736.